Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: Safe Banking Act Passed- News from (CSE: $HARV.C) (TSX: $VFF.TO) (NASDAQ: $VFF) (TSX.V: $PURE.V) (NYSE: $CGC)
Delta, Kelowna, BC –September 26 , 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2019/cannabis-potcasts/09261HARV-VFF-PURE-CGC.asp
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts
In today’s podcast we look at a few early announcements.
But first, yesterday the U.S. House of Representatives voted in favor of the Secure and Fair Enforcement (SAFE) Banking Act, a landmark bill that would provide safe harbor and guidance to financial institutions that work with legal cannabis businesses. The historic vote was the first time that a standalone marijuana bill has come before the full House. The vote needed a two-thirds majority to pass and was supported by 321 votes in favor to 103 against.
For years, cannabis businesses have been hamstrung by their inability to access bank financing for acquisitions, operations and expansion. It has also forced the industry to operate largely in cash.
While the Democratic-controlled House of Representatives voted to pass the bill protecting banks that work with the marijuana industry, some analysts are still warning that the measure isn’t likely to become law in 2019 as it faces a tough road in the Republican-controlled Senate.
The chances of enactment this year for the bill — known as the Secure And Fair Enforcement (SAFE) Banking Act — have risen to 1 in 3, up from 1 in 5, reckons Ian Katz, an analyst at Capital Alpha Partners. Those still aren’t great odds, however. “We remain skeptical for now,” Katz said in a note before the House vote, though he added that the chances could get better “if we see meaningful signals from the Senate in the next few weeks.”
Many in the industry are also looking at the MORE Act as the next legislation to hopefully pass through the house. The Marijuana Opportunity Reinvestment and Expungement (MORE) Act would remove cannabis from the Controlled Substances Act and take steps to begin repairing the harms of the war on drugs. The bill is sponsored by House Judiciary Committee Chairman, Jerrold Nadler (D-NY), who has already signaled that he is committed to advancing it through the House.
Also, StrainprintR Technologies Ltd., the leader in cannabis data and analytics, announced the release of The Canadian Medical Cannabis Experience: A 2019 Patient Retrospective, the latest Strainprint research publication designed to support the entire cannabis industry with meaningful insights based on the technology leader's unique and broad-based patient-led data. The Report features thorough analysis of more than 800,000 real-time anonymous patient outcomes reported during the period from January to December 2018.
"We hear time and time again about the need for comprehensive resources like our Patient Retrospective Report," said Strainprint President, Dave Berg. "Medical cannabis hasn't had decades of clinical trials to form guidelines on dosing, onset and efficiency and with over 450 chemical constituents in every strain, it is not like studying single molecules in traditional pharma. So, real-world patient data is invaluable for medical professionals and industry stakeholders looking to make informed choices for their patients and businesses."
Strainprint aggregates anonymous patient-reported data from its award-winning mobile journaling App and through surveys and validated questionnaires from its online Strainprint Community. Strainprint has been collecting this unique and proprietary data since 2016 and it grows more granular by the day. Today, it is the largest data set of its kind in the world with more than 1.4 million sessions and 70 million data points on strain efficacy. It is the only cannabis consumption data tracked in real time against more than 1,600 lab-verified products by batch.
"Tracking symptomatic improvement against chemical profile (ingredients) by batch is the only way for the industry to advance the scientific understanding of cannabis," said Michelle Arbus, Strainprint VP of Research. "We are fortunate in Canada to have a federal program with very high lab testing requirements, consistent across the country, giving us the most standardardized products from which to study and the best chance at personalizing cannabis as a medicine."
The 2019 Patient Retrospective Report is the cutting edge of cannabis research and a major milestone for the cannabis industry. The Report analyzes user variables such as age, gender, region, usage frequency and efficacy by symptom and is the first research set able to identify which terpenes are active in the cannabis products that are reported to have the highest efficacy by symptom. A few key findings from the Report include:
● Muscle pain, anxiety, depression, joint pain and insomnia are the top five symptoms that patients treated with cannabis during the Report period;
● There are clear gender differences for the preferred choice of cannabis administration and the most effective methods of can vary by region, gender and age;
● Multiple cannabis species are reported to offer comparable relief for particular symptoms, supporting the hypothesis that it is more than the species or the THC:CBD content that determines efficacy of a strain;
● Patients overwhelmingly report positive and or neutral emotive effects from their medical cannabis use with very few unfavorable side effects. As well, the specific terpene profiles present in a strain can greatly impact the side effects; and
● There was no significant change in how or when patients treated their various symptoms after cannabis was legalized recreationally in Canada.
●
While more study is certainly needed, Strainprint has raised the bar for cannabis industry research with the largest and most granular real-world observational patient study available. Strainprint Reports complement this data with actionable insights and are available for purchase at https://strainprint.ca/strainprint-reports/.
As well, Investorideas recently interviewed Andrew Muroff the CEO of Strainrpint at the ICBC Conference in Vancouver, regarding the company's recent reports. To listen click here.
Harvest Health & Recreation, Inc. (CSE: HARV) (OTCQX: HRVSF) today announced an exclusive partnership with Last Prisoner Project ("LPP"), a new non-profit organization committed to making sure that every cannabis prisoner is released, welcomed home and supported by their community. Harvest is the first large cannabis company to create a proprietary program focused on job creation for formerly incarcerated prisoners that have been affected by the criminalization of cannabis. Harvest and LPP's "Prison to Prosperity" pipeline of talent will focus on facilitating re-entry of individuals impacted by the war on drugs back into society, through workshop training programs, with the goal of providing employment opportunities at Harvest locations nationwide.
According to the US Department of Justice Bureau of Justice Statistics, within three years of release over two-thirds of released prisoners are re-arrested, and within six years of release that number jumps to 79%. The "Prison to Prosperity" program is designed to reverse this statistic and demonstrates Harvest's continued commitment to social justice, diversity and inclusion. It is designed to bring restorative justice to communities most affected, while bringing positive economic impacts to the residents and communities that the company serves.
"Over 40,000 prisoners in the U.S. are currently serving sentences for cannabis charges. While many companies are focused on decriminalization, expungement and clemency, Harvest recognized that re-entry can be incredibly difficult without help," said Harvest Chief Executive Officer Steve White. "We've partnered with the Last Prisoner Project to provide training courses, workshops and funding to help individuals re-enter the job marketplace, with the hope of ultimately placing them in employment opportunities within our Harvest network."
"I launched the Last Prisoner Project out of the conviction that it is wrong to continue to punish people for something society has decided should no longer be illegal, and in the belief that if I asked the legal cannabis industry to contribute the funds needed to gain the release of our prisoners, cannabis companies would see it as an opportunity to do the right thing, to put the values cannabis teaches into action," said Steve DeAngelo, Founder of Last Prisoner Project. "I am pleased and heartened by the response so far from cannabis companies and by many world-renowned musicians, including Stephen and Damian Marley, Willie Nelson, and Eric Rachmany. This overwhelmingly positive response gives me high hopes and strong confidence that the day will come when the last cannabis prisoner on Planet Earth is free to come home to their families. Until then, our mission continues."
Harvest's "Prison to Prosperity" program will offer vocational training opportunities and educational programs specific to the cannabis industry for those who continue to be disadvantaged by a criminal record. The program will begin with a pilot project working in tandem with local reentry organizations in California and will roll out nationally at a later date.
Pure Global Cannabis Inc. (TSX.V: PURE) (OTC: PRCNF) announced the creation of a new business unit, PureCanna Solutions. This B2B brand will provide white label extraction, co-processing, co-manufacturing, tolling, and cannabis and CBD isolate and extract bulk sales.
PureCanna has already entered into negotiations with potential clients and suppliers to provide immediate access to the Company's extensive line of products and manufacturing techniques, which include packaging for dried flower, oils bottles, vape pens, and capsules. As the Company continues to upscale their manufacturing and processing capabilities, the creation of this new division will offer significant revenue generating potential with exceptional margins.
Pure Global CEO & President, Malay Panchal said, "This new division will allow us to quickly and substantially increase high margin sales by servicing industry partners who share the same vision of creating only the highest quality products. Adding CBD bulk sales, white label, and co-processing services leverages our existing capabilities and any underutilized capacity."
In preparation for this development, the Company submitted their readiness packages in early August for Health Canada approvals of Phase 2 of their Brampton facility expansion, which upon approvals will immediately allow for cultivation along with manufacturing capabilities of 20 to 30kg of cannabis extract for bulk sale via CO2 supercritical extraction. PureSinse is in the process of adding significantly more extraction capacity for hemp biomass processing in place of previously denominated cultivation rooms with target capacities of 100 to 200 tons annually and expected readiness in early H1 2020.
This represents the latest in a series of transformational announcements from Pure Global. The Company announced earlier this week the signing of a joint operating agreement with KMT-Hansa Corp. to cultivate, grow and process hemp and CBD products in China. In addition, Pure was recently granted their oil sales license from Health Canada.
Mr. Panchal continued, "PureCanna is set to become a leading provider of GMP and pharmaceutical grade CBD and cannabinoid isolates, ready to use formulations, co-manufacturing, and co-packaging services for CPG companies and LPs. I am very proud of the hard work that has gone into the development of this unit and look forward to forging new partnerships with some highly respected cannabis and CPG companies in Canada and globally."
Village Farms International, Inc. (TSX: VFF) (NASDAQ: VFF) today announced that it has ranked as the third top-performing company in Toronto Stock Exchange's (TSX) inaugural TSX30, a flagship program recognizing the 30 top-performing TSX stocks over a three-year period based on dividend-adjusted share price appreciation.
"Since Village Farms first publicly listed its shares in 2006, Toronto Stock Exchange has been an outstanding platform for investors to participate in the growth of our Company to one of the largest vertically integrated greenhouse growing operations in North America," said Michael DeGiglio, CEO and Founder, Village Farms International. "Now, leveraging more than three decades as a leader in large-scale, precision agriculture, we are adding to our legacy produce business with the biggest opportunity in our history as we pursue outsized, long-term growth potential in the cannabis and CBD markets."
"Although this award recognizes outstanding recent performance, Village Farms is only just beginning to realize the value of these significant new growth opportunities, which have transformed both our near- and long-term earnings potential, and which we expect will drive growth for years to come. Our financial results are just starting to benefit from the success of our 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production in Canada, Pure Sunfarms, which is already one of the most profitable companies in the industry. Moreover, financial performance in the coming quarters should reflect Pure Sunfarms recent ramp to full capacity at its first greenhouse, the planned doubling of capacity next year with the conversion of a second greenhouse, and the potential to more than double that capacity again through the option to add a third greenhouse."
"In parallel, in the United States we are aggressively pursuing the significant opportunity in hemp and CBD. We expect to generate our first hemp biomass sales later this year, and then rapidly transition into higher margin CBD crude oil and then our own CBD products, as we build a leading consumer packaged goods company in this exciting, high-growth market. All of this should drive even further value for our shareholders over both the short and long terms."
"We are extremely proud to present the TSX30, a new recognition program featuring some of the most compelling success stories among our listed issuers, including companies operating in traditional areas of strength like natural resources and also in newly defined sectors like clean tech and cannabis," said Loui Anastasopoulos, President, Capital Formation, TMX Group. "TSX listed companies play a vital role in Canada's capital markets and as we continue to evolve into a global leader, TSX remains committed to our work in support of this crucial ecosystem. Today, we congratulate the companies included in the inaugural TSX30 for all of their achievements and look forward to continuing to serve them along each stage of their growth path into the future."
Spectrum Therapeutics, the medical division of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) announced a donation to the Fondation de l'Hôpital du Sacré-Coeur de Montreal (Montreal Sacre Coeur Hospital Foundation) to support the Canadian Sleep and Circadian Network's ("CSCN") associated national campaign: Sleep On It which aims to raise awareness about the importance of good quality sleep on health.
Spectrum's donation to the campaign has been made, based on CSCN's request to support their initiative to organize the sleep scientific community around the question of cannabis use for sleep disorders. Although an increasing volume of anecdotal data indicates the growing usage of cannabis from individuals coping with sleep disorders, clinical scientific evidence on its effectiveness is still limited. Hence, via this donation, CSCN will be able to provide to the public, health management decision makers as well as the sleep scientific community, a review of currently available data and identify the research gaps that need to be filled. This review is expected to be completed during the second half of the 2020 calendar year.
By partnering with the leader in the cannabis industry, CSCN's objective is to combine the expertise of clinicians, physicians and researchers across the country to facilitate and scientifically support the development of a white paper based on a comprehensive review of all existing literature and facts about the use of cannabis in sleep disorder management. The report is also expected to be published during the second half of the 2020 calendar year and will introduce an updated clinical research program looking at all areas that impact quality of sleep, including pain, aging, and sleep disorders such as insomnia. Ultimately, the white paper will provide insights and guidance on future research directions and further requirements for evidence on the potential application of medical cannabis in treating sleep disorders.
"Good quality sleep is far more important to our long-term health than most people realize," commented Dr. Mark Ware, Chief Medical Officer, Canopy Growth. "We're just now beginning to explore the role cannabis can play in addressing sleep-related disorders. Patient feedback is very promising so far, and partnerships such as these will advance our understanding of the intriguing phenomenon of sleep that is so essential to our overall well-being."
"The legalization of cannabis in Canada has brought about a natural interest in the potential for cannabis in the treatment of sleeping disorders. We need to catalyze the development of collective efforts to further develop scientific knowledge platforms to inform policy, therapeutic practice, and prevention efforts about sleep and cannabis and to scientifically inform decision makers as well as the general public about the research needs to produce evidence based data on sleep and cannabis," commented Dr Julie Carrier, Scientific Director of the Canadian Sleep & Circadian Network and sleep researcher at the CIUSSS du Nord-de-l'Île-de-Montreal.
One in three Canadians don't get the recommended seven hours of sleep each night. The CSCN's mission is to mobilize the healthcare community to adopt an integrated approach towards improving outcomes and treatment of patients with sleep disorders.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info:
https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment